EG408191 Inhibitors
EG408191 inhibitors are a class of small molecules that specifically target and modulate the activity of a particular protein or enzyme, known by its identifier EG408191. These inhibitors are designed to bind to the active or allosteric site of the protein, leading to changes in its conformation and subsequently disrupting its function. The structure of these inhibitors often features heterocyclic scaffolds, aromatic moieties, and functional groups such as amides, sulfonamides, or ketones that contribute to their binding affinity and specificity. The chemical properties of EG408191 inhibitors are designed to ensure that they have optimal solubility, stability, and bioavailability, allowing them to effectively interact with their target protein under various experimental conditions. They may exhibit different levels of potency, selectivity, and duration of action depending on their chemical structure and the nature of their interaction with the protein.
In terms of their molecular characteristics, EG408191 inhibitors often undergo rigorous optimization to enhance their pharmacokinetic properties. This includes improving their metabolic stability to ensure they remain active for the desired duration, and minimizing off-target effects that could result in undesired biological activity. Structural modifications are commonly performed to fine-tune the inhibitors' binding affinities, allowing for highly selective inhibition of EG408191. Various analytical techniques, such as NMR spectroscopy, X-ray crystallography, and mass spectrometry, are utilized in characterizing the molecular interactions and conformational changes induced by these inhibitors. Moreover, the inhibitors are typically evaluated for their binding kinetics, including their on-rate and off-rate of binding, which contribute to their overall inhibitory effectiveness. EG408191 inhibitors are thus a versatile and highly specialized class of compounds, offering precise modulation of the protein's function for experimental and research applications.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
Thiol-reactive compound inhibiting SENP2. NEM covalently modifies cysteine residues in SENP2, disrupting its SUMO-specific endopeptidase activity and hindering the process of protein desumoylation. | ||||||
ML-792 | 1644342-14-2 | sc-507423 | 10 mg | $398.00 | ||
SENP2 inhibitor impacting SUMO-specific endopeptidase activity. ML-792 directly targets SENP2, potentially inhibiting its desumoylation function and interfering with the regulation of protein ubiquitination. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
HDAC inhibitor influencing SENP2. Anacardic Acid indirectly inhibits SENP2 by impacting histone acetylation, potentially disrupting its interaction with chromatin and affecting the regulation of protein desumoylation. | ||||||
2-D08 | 144707-18-6 | sc-507405 | 5 mg | $150.00 | ||
Inhibitor of SUMOylation. 2-D08 indirectly inhibits SENP2 by modulating the SUMOylation process, potentially influencing the targets and pathways regulated by SENP2-mediated desumoylation. | ||||||
Ginkgolic acid C17:1 | 111047-30-4 | sc-228252 sc-228252A sc-228252B | 5 mg 10 mg 20 mg | $285.00 $461.00 $851.00 | 2 | |
SENP inhibitor impacting SUMO-specific endopeptidase activity. Ginkgolic Acid directly targets SENP2, potentially disrupting its function in protein desumoylation and affecting the regulation of SUMO-modified proteins. | ||||||
Rabeprazole | 117976-89-3 | sc-204872 sc-204872A | 10 mg 25 mg | $349.00 $620.00 | 2 | |
Proton pump inhibitor affecting SENP2. Rabeprazole indirectly inhibits SENP2 by modulating intracellular pH, potentially influencing the stability and function of SENP2 and, consequently, the regulation of protein desumoylation. | ||||||
JIB 04 | 199596-05-9 | sc-397040 | 20 mg | $177.00 | ||
Jumonji histone demethylase inhibitor. JIB-04 indirectly influences SENP2 by impacting histone demethylation, potentially altering the chromatin landscape and affecting the regulatory networks associated with protein desumoylation. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
Cysteine protease inhibitor affecting SENP2. E-64 directly inhibits SENP2 by targeting its cysteine protease activity, potentially disrupting the process of protein desumoylation and influencing the regulation of protein ubiquitination. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
Jumonji histone demethylase inhibitor. GSK-J4 indirectly influences SENP2 by impacting histone demethylation, potentially altering the chromatin landscape and affecting the regulatory networks associated with protein desumoylation. | ||||||
Tubastatin A | 1252003-15-8 | sc-507298 | 10 mg | $114.00 | ||
HDAC6 inhibitor influencing SENP2. Tubastatin A indirectly inhibits SENP2 by impacting histone acetylation, potentially disrupting its interaction with chromatin and affecting the regulation of protein desumoylation. | ||||||